Our privacy policy describes how Fidessa uses cookies on our website. If you continue using our website, you are consenting to our use of cookies. OK

Why the big exchanges need to visit Amsterdam

My friend Nandini Sukamar at Bloomberg broke a story yesterday that Eurex is to compete with CME Europe by offering competitive FX contracts. So it looks like we are going to see a few more spats as the big boys vie for control over the European exchange-traded derivatives market. The CME is looking to launch its own competitive products to Eurex, and NASDAQ NLX is taking on both NYSE Liffe and Eurex with its own interest rate products. These are interesting developments, as history shows that few such attempts are successful. Lack of fungibility between competing contracts means that it is pretty tricky for a newcomer (however large) to wrestle the open interest away from an incumbent. This is crucial, as a deep pool of open interest is essential for traders so that they can easily exit any positions they take.

Whilst the jury is still out on whether the big boys will successfully knock lumps out of each other, a small Dutch venue looks like it is showing how it should be done. Intriguingly named, TOM (The Order Machine) has been taking on NYSE Liffe in the Dutch equity options market. To be fair it had a natural advantage in that the Dutch options market is uniquely retail, but it also developed two other effective strategies besides just being cheaper. First, it offers best execution and so is prepared to route orders onto NYSE Liffe if it is showing a better price. This ensures they get to see the flow in the first place. Second, in the event that TOM is forced to route an order to Liffe, its market makers effectively net this out so that the pool of open interest remains and grows with TOM.

As a result, in less than 2 years TOM can claim an effective market share of more than 25% in those contracts in which it competes with NYSE Liffe.

I don’t know what they’re smoking in the cafés of Amsterdam these days, but maybe it’s time some of the global exchanges paid them a visit.

Comments
2 Responses to “Why the big exchanges need to visit Amsterdam”
  1. Syed Mohammad Ali says:

    Interesting read, Steve! One que, don’t you think exchanges fear these moves with such regulatory differences/FSA standards specifically talk of TSE here in Japan. Just curious, what’s your thoughts on regulatory/compliance aspect of it. thx// Ali

  2. steve grob says:

    Thanks Syed – you’re right the regulatory compliance aspects are huge. Personally I would like to see the derivative exchanges try and launch innovative new products rather than look a likes. Since the VIX (and of course TOM) – can’t remember the last time we saw anything really new. I guess NLX would claim that they are innovating by combing the short and long end of the rate curve but most of the announcements seem to be just taking competitive pot shots at each other.

Leave a comment

Copyright © 2014 Fidessa group plc. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa group plc.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.